Key result
Low-dose aspirin use (75-100 mg/day) was associated with a reduced risk of developing dementia or mild cognitive impairment in cohort studies (RR 0.75), though this protective effect was not supported by randomized controlled trials.
Why the study?
Previous studies reporting whether aspirin buffers against mild cognitive decline and dementia in older adults remain controversial.
Does aspirin use reduce the incidence of dementia and mild cognitive decline in older adults without cognitive dysfunction at baseline?
Meta-Analysis (n=100,909)
Does aspirin use reduce the incidence of dementia and mild cognitive decline in older adults without cognitive dysfunction at baseline?
Relative Risk: 0.75 (95% CI 0.63–0.9)
While observational cohort studies suggest low-dose aspirin may reduce the risk of dementia and mild cognitive impairment, randomized controlled trials do not support this benefit.
No takes yet. Share an insight, caveat, or question.
Aspirin shows no significant reduction in MCI or dementia risk; challenges prior positive reports and leaves open need for targeted RCTs.
Li et al. (2021) conducted a meta-analysis in Incident dementia and mild cognitive decline (MCI) (n=100,909). Aspirin vs. Non-users or placebo was evaluated on Incidence of dementia and mild cognitive decline (MCI) in cohort studies (low-dose) (RR 0.75, 95% CI 0.63-0.9). Low-dose aspirin use (75-100 mg/day) was associated with a reduced risk of developing dementia or mild cognitive impairment in cohort studies (RR 0.75), though this protective effect was not supported by randomized controlled trials.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: